BioPharmSignal logoBioPharmSignal

Biotech News

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Vaxcyte (PCVX)VaxcyteClinical readout

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 Pivotal Noninferiority Trial Expected in the Fourth Quarter of 2026 At All Doses

Related news

PCVXVaxcyte2026-03-23 12:30 EST

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

PCVXVaxcyte2026-02-11 21:05 EST

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

VXRTVaxart2026-07-06 20:01 EST

Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine

GOVXGeoVax Labs2024-11-19 14:00 EST

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GSKGSK plc2025-04-30 08:17 EST

Nucala (mepolizumab) delivers clinically meaningful and statistically significant reduction in COPD exacerbations, with positive MATINEE trial results published in New England Journal of Medicine

GSKGSK plc2026-02-25 12:00 EST

ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen

VXRTVaxart2026-06-25 12:00 EST

Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial

View all latest news

Vaxcyte

Carrier-Sparing Vaccine Platform Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses. Adult VAX-31 Program VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The...

Recent company news

PCVXVaxcyte2026-08-05 20:05 EST

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-07-08 20:05 EST

Vaxcyte to Participate in Upcoming Investor Conferences

PCVXVaxcyte2026-06-02 20:05 EST

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

PCVXVaxcyte2026-05-06 20:05 EST

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-04-07 20:05 EST

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

Stock data

Close
58.89 USD
Market cap
6.85B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States